TANDEM DIABETES CARE INC

TNDM

$1.05B

Small Cap

NASDAQSurgical & Medical Instruments & ApparatusMedical devices🇺🇸North AmericaSan Diego2.5K employees

Tandem Diabetes Care, Inc. is an American medical-device company that develops and markets insulin pumps, automated insulin delivery systems and diabetes-management software. Headquartered in San Diego, California, its principal pump platforms are the t:slim X2 and Tandem Mobi, both of which use the company's Control-IQ+ software with compatible continuous glucose monitors (CGMs).

Website

Drugs in Pipeline

Phase 3 Programs

Upcoming Catalysts

Next Catalyst

None scheduled

Market Overview

Stock performance and key metrics

TNDM News

Catalyst Timeline

0 upcoming, 0 past

No catalysts found.

How TNDM's past catalysts played out

earningsNov 2025-9%earningsAug 2025-5%earningsNov 2022-8%earningsApr 2020+7%earningsAug 2019-5%earningsNov 2018+8%earningsApr 2018+11%earningsMar 2018+7%

Drug Pipeline

No drugs found in this phase.

📑

Catalyst DossierPRO

The full research note — thesis, the if-approved scenario, financials & smart money. Compiled by CeliA.

→

Market-Implied Move

Regulatory Approvals

Frequently asked questions

When is TANDEM DIABETES CARE INC's next FDA catalyst?→

CatalystAlert tracks every upcoming catalyst for TANDEM DIABETES CARE INC (TNDM) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.

How do I track TNDM biotech catalysts?→

Add TNDM to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow TANDEM DIABETES CARE INC's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply